406502-38-3

Basic information

• Product Name: N'-[1-(4-methanesulfonyl-phenyl)-methanoyl]-N-methyl-hydrazinecarbodithioic acid methyl ester
• Synonyms: N'-[1-(4-methanesulfonyl-phenyl)-methanoyl]-N-methyl-hydrazinecarbodithioic acid methyl ester
• CAS NO: 406502-38-3
• Molecular Weight: 318.442
• Mol File: 406502-38-3.mol

Chemical Properties

• CAS DataBase Reference: N'-[1-(4-methanesulfonyl-phenyl)-methanoyl]-N-methyl-hydrazinecarbodithioic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N'-[1-(4-methanesulfonyl-phenyl)-methanoyl]-N-methyl-hydrazinecarbodithioic acid methyl ester(406502-38-3)
• EPA Substance Registry System: N'-[1-(4-methanesulfonyl-phenyl)-methanoyl]-N-methyl-hydrazinecarbodithioic acid methyl ester(406502-38-3)

Safety Data

• Hazardous Substances Data: 406502-38-3(Hazardous Substances Data)

Upstream product

• 20184-94-5 N-methyl-hydrazinecarbodithioic acid methyl ester 
• 40913-92-6 4-methylsulfonylbenzoyl chloride 

Relevant articles and documents

Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: Metabolism-directed optimization studies towards orally bioavailable derivatives

The synthesis and optimization of pharmacokinetic parameters of structurally novel small PDE7 inhibitors is discussed.

Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors

The invention provides 1,3,4-thiadiazoles and 1,3,4-oxadiazoles having the following Formula I: in which, Y is S or O, R1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl or a polycyclic group, optionally substituted, R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl or aryl optionally substituted, R3 is X2—R′3, in which X2 is a binding group and R′3 is cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, or a polycyclic group; optionally substituted, or their pharmaceutically acceptable derivatives, a compound of Formula I, for their preparation, and processes for pharmaceutical compositions containing methods of using the compounds for the treatment of disorders for which a treatment by a PDE7 inhibitor is relevant.

New thiadiazoles and their use as phosphodiesterase-7 inhibitors

The invention provides 1,3,4-thiadiazoles having the following formula (I): in which,R1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl or a polycyclic group, optionally substituted,R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl or aryl optionally substituted,R3 is X2-R'3, in which X2 is a binding group and R'3 is cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, or a polycyclic group; optionally substituted, or their pharmaceutically acceptable derivatives, the process for their preparation and their use for the manufacture of a medicament for the treatment of disorders for which a treatment by a PDE7 inhibitor is relevant.